american diabetes association history of pancreatitis glp-1 receptor agonist The Use Glucagon-like Peptide-1 Agonists in Patients with Type 2 Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study Frontiers | Redefining pancreatogenic diabetes
Description
Accumulated evidence has shown that the RAAS is no longer considered to act just as an endocrine system, but also as a paracrine, autocrine and intracrine system
In three separate SUSTAIN trials, semaglutide 1 mg conferred a greater weight loss among adults with type 2 diabetes than exenatide 2 mg (Bydureon, AstraZeneca), dulaglutide 1.5 mg (Trulicity, Eli Lilly) and liraglutide 1.8 mg (Saxenda, Novo Nordisk)
New Formulations: Efforts are underway to create more convenient formulations, including longer-acting injectables that may only require monthly administration and improved oral versions
[DOI] [PubMed] [Google Scholar] 173.Nahra R., Wang T., Gadde K.M., Oscarsson J., Stumvoll M., Jermutus L., Hirshberg B., Ambery P
